Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
PF-07284892 | New project
SHP2 tyrosine phosphatase inhibitor
PF-07921585 (PD1-IL12) | New project
IL-12 partial agonist
PF-07985045 (KRAS Next Gen) | New project
selective KRAS inhibitor